Ceftaroline Fosamil for the Empiric Treatment of Hospitalized Adults with cSSTI: An Economic Analysis from the Perspective of the Spanish National Health System.

Torres, Antoni; Soriano, Alex; Rivolo, Simone; Remak, Edit; Peral, Carmen; Kantecki, Michal; Ansari, Wajeeha; Charbonneau, Claudie; Hammond, Jennifer; Grau, Santiago; Wilcox, Mark

Torres, Antoni; Soriano, Alex; Rivolo, Simone; Remak, Edit; Peral, Carmen; Kantecki, Michal; Ansari, Wajeeha; Charbonneau, Claudie; Hammond, Jennifer; Grau, Santiago; Wilcox, Mark.

Afiliação

Torres A; Servei de Pneumologia Hospital Clinic, University of Barcelona, IDIPAPS, CIBERES, ICREA, Barcelona, Spain.
Soriano A; Hospital Clínic of Barcelona,University of Barcelona, IDIBAPS, Barcelona, Spain.
Rivolo S; Modeling and Simulation, Evidera, London, UK.
Remak E; Formerly Modeling and Simulation, Evidera, Budapest, Hungary.
Peral C; Health Economics and Outcomes Research, Pfizer, Madrid, Spain.
Kantecki M; Global Medical Affairs, Pfizer, Paris, France.
Ansari W; Patient & Health Impact, Pfizer, New York, NY, USA.
Charbonneau C; Patient & Health Impact, Pfizer, Paris, France.
Hammond J; Global Product Development, Pfizer, Collegeville, PA, USA.
Grau S; Hospital del Mar,Universitat Pompeu Fabra, Barcelona, Spain.
Wilcox M; University of Leeds, Leeds, UK.

Clinicoecon Outcomes Res ; 14: 149-161, 2022.

Article em En | MEDLINE | ID: mdl-35330907

Palavras-chave

Spain; ceftaroline fosamil; complicated skin and soft tissue infection; cost-consequences

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Health_economic_evaluation / Prognostic_studies Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google